Home Care Agencies for Sale: Selling a Home Health Agency

Price is set by adjusted EBITDA size tier and payer mix, not by revenue alone, and the two care models value differently.

Private-pay personal care runs from an estimated 3.5x to 4.5x EBITDA below $500,000, up to 8.5x to 11.0x-plus above $5 million, with the top of the range reserved for genuinely platform-quality agencies, not the typical listing.

Medicaid personal care, HCBS, and MLTSS agencies trade lower for the same size, roughly 4.0x to 8.5x depending on state reimbursement trends, wage mandates, MCO contract concentration, and EVV compliance. One waiver program or MCO above 40% to 50% of revenue is a discount trigger buyers will flag immediately.

Medicare-certified skilled home health carries the widest range: 4.5x to 10.0x at base, and 6.5x up to 12.0x-plus in a premium competitive process, where the premium requires mature transferable enrollment, clean surveys, and sound OASIS and PDGM billing controls. A valid, transferable certificate of need can add an estimated 1.0x to 2.5x EBITDA where it creates a real barrier to entry, but that premium disappears the moment the CON isn't transferable or the census is weak.

Two named public deals show revenue multiples at scale, for context: Addus paid about 1.25x revenue for Gentiva's personal care book, and Pennant paid about 0.77x revenue for its 54-location divestiture package, which was roughly two-thirds home health and one-third hospice. Neither is a general rule; both reflect the specific service mix and, in Pennant's case, a regulator-driven divestiture rather than a normal auction.

The Medicare-certified segment carries one more live variable in 2026: CMS's nationwide HHA enrollment moratorium, effective 13 May 2026, blocks initial enrollments and most changes in majority ownership that would require a new enrollment. A mature, already-certified agency becomes more strategically scarce under this rule, but the same rule can make a proposed deal structure uncloseable. Confirm before you sign an LOI whether your transaction requires an initial enrollment or a non-exempt change in majority ownership.

What actually moves the multiple

Enterprise value is set cash-free, debt-free, on normalized working capital delivered at close. Small asset deals typically fund 70% to 90% at close, with the balance in a seller note, earnout, or holdback; SBA-backed buyers may also require seller standby debt. Institutional deals commonly place 5% to 15% of value in escrow for 12 to 24 months, and rollover equity of roughly 10% to 30% is common, though not universal, when a PE buyer wants the owner to stay on.

A full process runs 6 to 12 months from readiness to close, and a clean, well-represented deal can close 60 to 90 days after LOI, though state review, payer credentialing, CON approval, and the 2026 moratorium can add months.

For the full breakdown of how buyers translate these numbers into a valuation range for your specific agency, see our home care and home health valuation guide and use the valuation calculator.

Buyers generally prefer an asset purchase, because it delivers a stepped-up basis and lets acquired goodwill, licenses, and other Section 197 intangibles amortize over 15 years. Sellers generally prefer an equity sale, because it's more likely to produce capital-gain treatment on the whole transaction rather than a mix of ordinary and capital income from asset allocation. Asset and equity sales are also reported differently: an asset sale requires Form 8594 under IRC Section 1060, with a consistent purchase-price allocation agreed by both sides.

See our asset sale versus stock sale guide for the mechanics that apply across healthcare sellers generally. Regulatory continuity can push you toward an equity structure even if the tax math favors assets, because the licensed entity survives an equity sale and payer credentialing is less likely to require a full re-enrollment. That continuity comes at a cost: the entity's known, unknown, and contingent historical liabilities come with it. C-corporation owners should also model an asset sale followed by liquidation carefully, since it can trigger tax at both the corporate and shareholder level. And if you were counting on Qualified Small Business Stock treatment, don't: IRC Section 1202 excludes health-services businesses from the QSBS definition, so most home health and direct-care operating companies don't qualify. Get a structure-specific tax model built before you sign an LOI, not after the purchase agreement is drafted.

Say your agency is a Medicaid-funded personal care business with $2.1 million in adjusted EBITDA, no single MCO above 30% of revenue, a documented 88% caregiver fill rate, and clean EVV compliance. That size and profile lands in the $1.5 million to $3 million EBITDA tier at 5.0x to 6.5x, which is $10.5 million to $13.65 million in enterprise value before debt-like items and a working-capital true-up. If instead one MCO represents 55% of revenue and EVV exceptions are frequent, expect the buyer pool to shrink to strategics willing to underwrite that concentration risk, and the applicable multiple to compress toward the low end of the range or below it.

If you're weighing whether to sell a home care or home health agency this year, the first useful thing to establish is which valuation tier you're actually in and whether your transfer structure survives the 2026 CMS moratorium and the 36-month rule. We work sell-side with owners of profitable home care and home health agencies across the size spectrum described above. Start a confidential conversation with our team, no listing, no broad marketing, before you decide anything.